TABLE 5.
Fasting GLP-1 values before and after dietary intervention
| Author, (y), n | GLP-1 assay | Intervention Participant characteristics |
Fasting GLP-1 values (pmol/L) |
Δ | Results | ||
|---|---|---|---|---|---|---|---|
| Baseline | Endline | ||||||
| Ohlsson et al. 2018 [79] n = 30 |
Bio-Plex Pro Human Diabetes 10-plex panel (Bio-Rad Laboratories)1 | 12 wks Okinawa-based ND (slight energy reduction) T2DM (BMI:: 29.9 kg/m2) |
0.81# | 0.54# | - 0.27 | ↓ fasting values compared with baseline | |
| Arjmand et al. 2022 [73] n = 37 RCT |
ELISA (Bioassay Technology Laboratory)2 | 12 wks Calorie restricted MIND diet (n = 22) vs. hypocaloric diet (n = 15) (1500 kcal/day, 50%–55% CH, 30% F, 15%–20% P) OW (BMI:: 32 kg/m2) |
MIND diet | 12.8# | 14.7# | 1.9 | ↑ fasting values after the MIND diet compared with baseline and hypocaloric diet |
| Hypocaloric diet | 8.8# | 7.4# | -1.4 | ||||
Fasting GLP-1 concentrations as well as Δ (endline value – baseline value) before and after dietary intervention are listed. Under “results” only significant results are listed.
#original data, ↑ higher GLP-1 secretion in comparison to referred groups, ↓ lower GLP-1 secretion in comparison to referred groups. Details on GLP-1 assays as stated in the publications or according to manufacturer instructions:
Abbreviations: CH, carbohydrates; CV, coefficient of variation; F, fat; GLP-1, glucagon-like peptide 1; MIND, Mediterranean-DASH Intervention for Neurodegenerative Delay; ND, healthy Nordic diet; OW, overweight; P, protein; RCT, randomized controlled trial; T2DM: type 2 diabetes mellitus.
n.a.;
sensitivity: 1.3 pM; intra-assay CV: 2.8%–5.2%.